UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

• J.G. Berdeja,
• D. Madduri,
• S.Z. Usmani,
• I. Singh,
• E. Zudaire,
• T.M. Yeh,
• A.J. Allred,
• Y. Olyslager,
• A. Banerjee,
• J.D. Goldberg,
• J. Schecter,
• D. Geng,
• X. Wu,
• M.J. Carrasco-Alfonso,
• S. Rizvi,
• F. Fan,
• A. Jakubowiak,
• S. Jagannath

Affiliations

J.G. Berdeja

Sarah Cannon Research Institute, Nashville, United States

D. Madduri

Mount Sinai Medical Center, New York, United States

S.Z. Usmani

Levine Cancer Institute-Atrium Health, Charlotte, United States

I. Singh

Janssen R&D, Spring House, United States

E. Zudaire

Janssen R&D, Spring House, United States

T.M. Yeh

Janssen R&D, Raritan, United States

A.J. Allred

Janssen R&D, Spring House, United States

Y. Olyslager

Janssen R&D, Beerse, Belgium

A. Banerjee

Janssen R&D, Spring House, United States

J.D. Goldberg

Janssen R&D, Raritan, United States

J. Schecter

Janssen R&D, Raritan, United States

D. Geng

Legend Biotech USA Inc., Piscataway, United States

X. Wu

Legend Biotech USA Inc., Piscataway, United States

M.J. Carrasco-Alfonso

Legend Biotech USA Inc., Piscataway, United States

S. Rizvi

Legend Biotech USA Inc., Piscataway, United States

F. Fan

Nanjing Legend Biotech, Nanjing, China

A. Jakubowiak

University of Chicago, Chicago, United States

S. Jagannath

Mount Sinai Medical Center, New York, United States